Treatment and Survival of U.S. Vietnam Veterans With Concurrent Lymphoid Malignancies
Military Medicine · 2025
DOI: 10.1093/milmed/usaf061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Military Medicine, 2025. Verfasst von Matthew R Moldenhauer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: Veterans, Lymphoma. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Clinical Science Research and Development, Lymphoma Research Foundation.
Abstract (Originalsprache)
Introduction
In Vietnam veterans, exposure to military toxicants, such as Agent Orange, may be associated with lymphoid malignancies. Toxicant exposure may increase the likelihood of being diagnosed with concurrent lymphoid malignancies, which can occur as composite, discordant, or transformed lymphomas. Materials and Methods We conducted a large, retrospective case-control study using the national VA Central Cancer Registry to identify cases of concurrent lymphoid malignancies compared to controls of single lymphoid malignancies and the association with Agent Orange.
Results
The occurrence of concurrent lymphoid malignancies was rare (n = 128/32,889, 0.4%). The most common concurrent lymphoid malignancy combinations were chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma, CLL and plasma cell neoplasms, CLL and marginal zone lymphoma, and diffuse large B-cell lymphoma and follicular lymphoma. Agent Orange exposure was not associated with increased odds of being diagnosed with concurrent lymphoid malignancies. Though limited in sample size, patients with concurrent lymphoid malignancies did not appear to have a worse survival compared to patients with single lymphoid malignancies. In our qualitative analysis of treatments for those with concurrent diagnoses, veterans primarily underwent first-line treatment for the more aggressive diagnosis, with few requiring treatments for both diagnoses during their clinical course.
Conclusions
In this Vietnam Era cohort, Agent Orange exposure did not appear to influence the development of concurrent lymphoid malignancies. Having a diagnosis of concurrent lymphoid malignancies did not appear to significantly affect patient survival. This will inform counseling of veterans with Agent Orange exposure and has implications for future policy development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
- Section of Hematology/Oncology, VA Long Beach Healthcare System, Long Beach, CA 90822, USA.
- Division of Hematology/Oncology, University of California Irvine, Orange, CA 92868, USA.
- Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA 92612, USA.
ORCID-Profile: Helen Ma
Förderung
- Clinical Science Research and Development
- Lymphoma Research Foundation
Zitieren
APA
Moldenhauer, M. R., Gupta, P., & Ma, H. (2025). Treatment and Survival of U.S. Vietnam Veterans With Concurrent Lymphoid Malignancies. Military Medicine. https://doi.org/10.1093/milmed/usaf061
Vancouver
Moldenhauer MR, Gupta P, Ma H. Treatment and Survival of U.S. Vietnam Veterans With Concurrent Lymphoid Malignancies. Military Medicine. 2025. doi:10.1093/milmed/usaf061
BibTeX
@article{Moldenhauer2025,
author = {Moldenhauer, Matthew R and Gupta, Pankaj and Ma, Helen},
title = {Treatment and Survival of U.S. Vietnam Veterans With Concurrent Lymphoid Malignancies},
journal = {Military Medicine},
year = {2025},
doi = {10.1093/milmed/usaf061}
}
EUVIMED